Advertisement intended for health care professionals

l

Megakaryocytic Emperipolesis

Megakaryocytic Emperipolesis
#00064588
Author: Isaac McCool, MD; Zeba Singh, MBBS
Category: Laboratory Hematology > Basic cell morphology > Morphologic variants of platelets (cross-reference with specific diagnoses when appropriate > Megakaryocytes
Published Date: 08/07/2023

A 57-year-old female with a seven-year history of IgG kappa multiple myeloma, refractory to numerous treatments (carfilzomib, lenalidomide, dexamethasone, melphalan with autologous stem cell transplant, lenalidomide maintenance, and salvage daratumumab, pomalidomide and dexamethasone) undergoes a bone marrow biopsy for concern for relapse.  Peripheral blood reveals normocytic anemia and thrombocytopenia (hemoglobin 11.4 g/dL, MCV 88.5 fL, platelets 105K/μL); serum protein electrophoresis and immunofixation identify an IgG kappa monoclonal protein (0.81 g/dL).  The bone marrow biopsy confirms diffuse involvement by the plasma cell neoplasm (70% by CD138 immunostaining).  Within the aspirated bone marrow, rare megakaryocytes were observed containing granulocytes (100x objective, total magnification x1000), an incidental finding known as emperipolesis.

Megakaryocytic emperipolesis is a process in which hematopoietic cells migrate through the megakaryocytic canalicular system to gain access to circulation.  The travelling cells are encased within a vacuole (an emperisome), released into the host cytoplasm, fuse with the demarcation membrane system and exchange membrane with the host megakaryocyte, enhancing thrombocytogenesis.  After 10-40 minutes, the cells leave intact.  This cell-to-cell interaction must be kept in mind as a mimic when evaluating hemophagocytosis.  Also, increased emperipolesis can be seen in blood loss, reactive thrombocytosis, immune thrombocytopenia, gray platelet syndrome, myeloproliferative neoplasms and myelodysplastic neoplasms.

Advertisement intended for health care professionals